Maria-Magdalena Guichard1, Géraldine Peters1, Cengiz Tuerksever1, Christian Pruente2,3, Katja Hatz4,5. 1. Vista Klinik, Binningen, Switzerland. 2. Department of Ophthalmology, University of Basel, Basel, Switzerland. 3. Department of Ophthalmology, Kantonsspital Liestal, Liestal, Switzerland. 4. Vista Klinik, Binningen, Switzerland, katja.hatz@vista.ch. 5. Department of Ophthalmology, University of Basel, Basel, Switzerland, katja.hatz@vista.ch.
Abstract
PURPOSE: To analyze the efficacy and outcome predictors of SD-OCT (spectral-domain optical coherence tomography)-driven ranibizumab treatment in patients with choroidal neovascularization due to myopia (mCNV). METHODS: This prospective investigator-initiated study includes 20 patients with treatment-naïve mCNV. Evaluation included best-corrected visual acuity (BCVA), morphological SD-OCT parameters, and treatment frequency. RESULTS: From baseline to month 12, BCVA improved from 58.5 ± 16.9 to 66.1 ± 14.9 letters. Central retinal thickness (CRT) significantly decreased, and qualitative SD-OCT parameters improved. Better baseline visual acuity (VA), lower spherical equivalent, better inner/outer segment line and external limiting membrane integrity showed a significant positive effect on BCVA outcome. Less fluctuation in CRT (worst minus best CRT) indicated better BCVA at 12 months. No serious adverse events occurred. CONCLUSIONS: SD-OCT-guided intravitreal ranibizumab treatment in mCNV was efficient and safe. We determined useful predictive factors in regard to VA outcome after 12 months. The Author(s). Published by S. Karger AG, Basel.
PURPOSE: To analyze the efficacy and outcome predictors of SD-OCT (spectral-domain optical coherence tomography)-driven ranibizumab treatment in patients with choroidal neovascularization due to myopia (mCNV). METHODS: This prospective investigator-initiated study includes 20 patients with treatment-naïve mCNV. Evaluation included best-corrected visual acuity (BCVA), morphological SD-OCT parameters, and treatment frequency. RESULTS: From baseline to month 12, BCVA improved from 58.5 ± 16.9 to 66.1 ± 14.9 letters. Central retinal thickness (CRT) significantly decreased, and qualitative SD-OCT parameters improved. Better baseline visual acuity (VA), lower spherical equivalent, better inner/outer segment line and external limiting membrane integrity showed a significant positive effect on BCVA outcome. Less fluctuation in CRT (worst minus best CRT) indicated better BCVA at 12 months. No serious adverse events occurred. CONCLUSIONS:SD-OCT-guided intravitreal ranibizumab treatment in mCNV was efficient and safe. We determined useful predictive factors in regard to VA outcome after 12 months. The Author(s). Published by S. Karger AG, Basel.
Authors: Adnan Tufail; Nirodhini Narendran; Praveen J Patel; Sobha Sivaprasad; Winfried Amoaku; Andrew C Browning; Olayinka Osoba; Richard Gale; Sheena George; Andrew J Lotery; Mohammed Majid; Martin McKibbin; Geeta Menon; Christopher Andrews; Christopher Brittain; Aaron Osborne; Yit Yang Journal: Ophthalmology Date: 2013-09 Impact factor: 12.079
Authors: Rufino M Silva; José M Ruiz-Moreno; Paulo Rosa; Angela Carneiro; João Nascimento; Luís F Rito; M Luz Cachulo; Fausto Carvalheira; Joaquim N Murta Journal: Retina Date: 2010-03 Impact factor: 4.256
Authors: Andre J Witkin; Tony H Ko; James G Fujimoto; Annie Chan; Wolfgang Drexler; Joel S Schuman; Elias Reichel; Jay S Duker Journal: Am J Ophthalmol Date: 2006-09-01 Impact factor: 5.258
Authors: K Ohno-Matsui; T Yoshida; S Futagami; K Yasuzumi; N Shimada; A Kojima; T Tokoro; M Mochizuki Journal: Br J Ophthalmol Date: 2003-05 Impact factor: 4.638
Authors: P A Keane; S Liakopoulos; K T Chang; F M Heussen; S C Ongchin; A C Walsh; S R Sadda Journal: Br J Ophthalmol Date: 2008-06-27 Impact factor: 4.638